% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Krilaviciute:290221,
      author       = {A. Krilaviciute$^*$ and R. Kaaks$^*$ and P. Seibold$^*$ and
                      M. de Vrieze$^*$ and J. Lakes and J. P. Radtke and M. Kuczyk
                      and N. N. Harke and J. Debus$^*$ and C. Fink$^*$ and K.
                      Herkommer and J. E. Gschwend and V. H. Meissner and A.
                      Benner$^*$ and G. Kristiansen and B. Hadaschik$^*$ and C.
                      Arsov and L. Schimmöller and G. Antoch and F. L. Giesel and
                      M. Makowski and F. Wacker and H.-P. Schlemmer$^*$ and N.
                      Becker$^*$ and P. Albers$^*$},
      title        = {{R}isk-adjusted {S}creening for {P}rostate
                      {C}ancer-{D}efining the {L}ow-risk {G}roup by {D}ata from
                      the {PROBASE} {T}rial.},
      journal      = {European urology},
      volume       = {86},
      number       = {6},
      issn         = {0302-2838},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2024-01039},
      pages        = {493-500},
      year         = {2024},
      note         = {#EA:C130#LA:C130# / 2024 Dec;86(6):493-500},
      abstract     = {Risk-adjusted screening for prostate cancer (PCa) aims to
                      reduce harms by less frequent retesting, especially in men
                      at a low risk of PCa. Definitions of low risk are based
                      mainly on studies in men starting screening at age 55-60
                      yr.To identify men at age 45 yr with a low risk of PCa.A
                      population-based, risk-adjusted PCa screening trial was
                      conducted in Germany using baseline prostate-specific
                      antigen (PSA) starting in young men (PROBASE).PSA
                      measurements starting at the age of 45 yr.The incidence of
                      PCa within 5 yr was assessed in men with screen-negative
                      baseline PSA <1.5 ng/ml compared with those with PSA
                      1.5-≤3.0 ng/ml.Of 23301 men who received a first PSA test
                      at age 45 yr, $0.79\%$ had a screen-positive PSA value of
                      ≥3 ng/ml. Among the $89\%$ of men who had a
                      screen-negative baseline PSA value of <1.5 ng/ml, only
                      $0.45\%$ received a positive PSA test ≥3 ng/ml upon
                      retesting after 5 yr. By contrast, for those with a
                      screen-negative baseline PSA value of 1.5-3 ng/ml, $13\%$
                      surpassed 3 ng/ml upon biennial testing within the next 4
                      yr. The incidence of PCa in subsequent screening rounds
                      increased with increasing baseline PSA levels, from 0.13 per
                      1000 person-years for men with initial PSA level of <1.5
                      ng/ml to 8.0 per 1000 person-years for those with PSA levels
                      of 1.5-3.0 ng/ml. A limitation is a follow-up time of only 5
                      yr, so far.Men with baseline PSA <1.5 ng/ml at age 45 yr are
                      at a very low risk of PCa over the next 5 yr.The PROBASE
                      study showed that men with baseline prostate-specific
                      antigen (PSA) <1.5 ng/ml at age 45 yr have a very low
                      prostate cancer detection rate over 5 yr and do not need PSA
                      retesting during this time.},
      keywords     = {Low risk (Other) / Prostate cancer (Other) /
                      Prostate-specific antigen (Other) / Screening (Other)},
      cin          = {C130 / C020 / E050 / C060 / ED01 / E010},
      ddc          = {610},
      cid          = {I:(DE-He78)C130-20160331 / I:(DE-He78)C020-20160331 /
                      I:(DE-He78)E050-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)ED01-20160331 / I:(DE-He78)E010-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38749854},
      doi          = {10.1016/j.eururo.2024.04.030},
      url          = {https://inrepo02.dkfz.de/record/290221},
}